Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy

Journal of Clinical Investigation

Volumn 107, Issue 4, 2001, Pages 431-438

  Philpott, S ^a   Weiser, B ^a   Anastos, K ^a   Ramirez Kitchen, C M ^a   Robison, E ^a   Meyer III, W A ^a   Sacks, H S ^a   Mathur Wagh, U ^a   Brunner, C ^a   Burger, H ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PATHOGENESIS;

EID: 0035114185     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11526     Document Type: Article

References (36)

1. Identification of a major coreceptor for primary isolates for HIV-1
2. A dual-tropic, primary HIV-1 isolate that uses fusin and the B-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusin cofactors
3. A new classification for HIV-1
4. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of CCR-5 chemokine receptor gene
5. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
6. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression
7. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
8. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
9. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
10. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell tropic virus populations
11. In vivo HIV-1 infection of CD45RA+CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ cell decline
12. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
13. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
14. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
15. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
16. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
17. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
18. Association of race and gender with HIV-1 RNA levels and immunologic progression
19. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission
20. Molecular cloning of full-length HIV-1 genomes directly from plasma viral RNA
21. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 cytium-inducing phenotype
22. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type lgp 120 involved in CCR5 utilization
23. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
24. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
25. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
26. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine
27. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy
28. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy
29. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
30. Heterogeneous spectrum of coreceptor usage among variants within dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies
31. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry
32. Decay characteristics of HIV-1-infected compartments during combination therapy
33. Latent infection of CD4+ cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
34. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
35. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
36. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population